期刊文献+

胃肠间质瘤若干热点问题及其进展 被引量:1

Gastrointestinal Stromal Tumours:Hot Issues and Recent Advances
下载PDF
导出
摘要 近年来,胃肠间质瘤(GIST)在活检时机选择、分子标志物、基因突变分析、预后因素(肿瘤危险分级)、靶向治疗效果评估方法、腹腔镜手术进展、进展期患者术前药物治疗及手术时机选择、靶向治疗耐药机制及应对策略等热点问题达成诸多共识。活检、分子标志物、基因突变分析对GIST早期诊断及指导治疗具有重要意义。进展期患者应早期行术前评估,并且进行危险分级,对手术风险较大患者可先进行术前治疗,并早期进行疗效评价,对于肿瘤降级后可行手术切除者尽早手术切除,而对于靶向治疗无反应的患者,应尽早行基因分析,并根据不同耐药机制采取不同应对策略。 Consensus on the diagnosis and treatment of gastrointestinal stromal tumours(GISTs) has been achieved with the multi-disciplinary research recently,including biopsy timing,molecular markers,gene mutation analysis,prognostic factors(risk stratification systems),targeted treatment effect assessment,laparoscopic surgery progress,preoperative medication and timing of surgery in advanced GISTs,resistance mechanism and response strategy of targeted therapy.Biopsy,molecular markers,and gene mutation analysis of GIST are of great significance for early diagnosis and treatment.Early preoperative evaluation and risk classification should be performed in advanced GISTs.Preoperative treatment can be carried out in patients with high risk of operation,followed by feasible excision as soon as possible after the reduction of tumor grade.However,if the patient is unresponsive to the targeted therapy,gene analysis should be performed as soon as possible,followed by different theraputic strategies based on different mechanisms of drug resistance.
出处 《医学综述》 2013年第13期2360-2364,共5页 Medical Recapitulate
关键词 胃肠间质瘤 热点问题 进展 Gastrointestinal stromal tumor Hot issues Recent advances
  • 相关文献

参考文献22

  • 1Hirota S,Isozaki K,MoriyamaY,et al.Gain-of-function mutations ofc-kit in human gastrointestinal stromal tumors[J].Science,1998,279(5350):577-580.
  • 2Blackstein ME,Blay JY,Corless C,et al.Gastrointestinal stromaltumours:consensus statement on diagnosis and treatment[J].Can JGastroenterol,2006,20(3):157-163.
  • 3中国胃肠间质瘤诊断治疗专家共识(2011年版)[J].临床肿瘤学杂志,2011,16(9):836-844. 被引量:104
  • 4Miettinen M,Wang ZF,Lasota J.DOG1 antibody in the differentialdiagnosis of gastrointestinal stromal tumors:a study of 1840 cases[J].Am J Surg Pathol,2009,33(9):1401-1408.
  • 5Lucas DR.Clinicopathology and molecular diagnostics of gastroin-testinal stromal tumors[J].Curr Probl Cancer,2011,35(5):233-244.
  • 6Rios-Moreno MJ,Jaramillo S,Pereira Gallardo S,et al.Gastrointes-tinal stromal tumors(GISTs):CD117,DOG-1 and PKCθexpres-sion.Is there any advantage in using several markers?[J].PatholRes Pract,2012,208(2):74-81.
  • 7Sevinc A,Camci C,Sari I,et al.Cyclooxygenase-2 expression ingastrointestinal stromal tumours[J].Asian Pac J Cancer Prev,2010,11(4):849-853.
  • 8Sciot R,Debiec-Rychter M,Daugaard S,et al.Distribution andprognostic value of histopathologic data and immunohistochemicalmarkers in gastrointestinal stromal tumours(GISTs):An analysis ofthe EORTC phaseⅢtrial of treatment of metastatic GISTs withimatinib mesylate[J].Eur J Cancer,2008,44(13):1855-1860.
  • 9Wardelmann E,Buttner R,Merkelbach-Bruse S,et al.Mutationanalysis of gastrointestinal stromal tumors:increasing significancefor risk assessment and effective targeted therapy[J].VirchowsArch,2007,451(4):743-749.
  • 10Gastrointestinal Stromal Tumor Meta-Analysis Group(MetaGIST).Comparison of two doses of imatinib for the treatment of unresect-able or metastatic gastrointestinal stromal tumors:a meta-analysis of1,640 patients[J].J Clin Oncol,2010,28(7):1247-1253.

二级参考文献48

  • 1贺慧颖,方伟岗,钟镐镐,李燕,郑杰,杜娟,衡万杰,吴秉铨.165例胃肠道间质瘤中c-kit和PDGFRA基因突变的检测和临床诊断意义[J].中华病理学杂志,2006,35(5):262-266. 被引量:73
  • 2Li J,Gong FJ,Shen L,et al.Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumour[J].Euro J Sur Oncol,2011,37(4):319-324.
  • 3Corless CL,Ballman KV,Antonescu C,et al.Relation of tumor pathologic and molecular features to outcome after surgical resection of localized primary gastrointestinal stromal tumor (GIST):Results of the intergroup phase Ⅲ trial ACOSOG Z9001[J].J Clin Oncol,2010,28 (15 Suppl):a10006.
  • 4Joensuu H,Eriksson M,Hartmann J,et al.Twelve vs 36 months of adjuvant imatinib as treatment of operable GIST with a high risk of recurrence:final results of a randomized trial (SSGXⅧ/AIO)[J].J Clin Oncol,2011,29(Suppl):aLBAI.
  • 5DeMatteo RP,Owzar K,Antonescu CR,et al.Efficacy of adjuvant imatinib mesylate following complete resection of localized,primary gastrointestinal stromal tumor (GIST) at high risk of recurrence:The U.S.Intergroup phase Ⅱ trial ACOSOG Z9000[C/OL].2011[2011-07-29].http://www.anco.org/ascov2/Meetings/Abstracts? &vmview = abst-detail-view&confID =53&abstractID = 10450.
  • 6Demetri GD,von Meherm M,Blanke CD,et al.Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors[J].N Engl J Med,2002,347(7):472-480.
  • 7Zalcberg JR,Verweij J,Casali PG,et al.Outcome of patients with advanced gastrointestinal stromal tumours croasing over to a daily imatinib dose of 800 mg after progression on 400 mg[J].Eur J Cancer,2005,41 (12):1751-1757.
  • 8Rios M,Lecesne A,Bui B,et al.Interruption of imatinib (IM)in GIST patients with advanced disease after one year of treatment:Updated results of the prospective French Sarcoma Group randomized phase Ⅲ trial on long term survival[J].J Clin Oncol,2007,25(18 Suppl):10016.
  • 9Raut CP,Posner M,Dessi J,et al,Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors[J].J Clin Oncol,2006,24(15):2325-2331.
  • 10DeMatteo RP,Maki RG,Singer S,et al.Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor[J].Ann Surg,2007,245 (3):347-352.

共引文献103

同被引文献8

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部